Hikma Pharmaceutical | HIK - Selling And Administration Expenses

Hikma Pharmaceutical reported $253M in Selling and Administration Expenses for its second fiscal semester of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Selling And Administration Expenses Change
AstraZeneca AZN:LN USD 3.53B 174M
Bayer BAYN:GR EUR 4.43B 347M
Fresenius FRE:GR EUR 1.82B 210M
Fresenius Medical Care FMS:US EUR 955M 34.61M
Genmab GEN:DC DKK 921M 251M
GlaxoSmithKline GSK:LN GBP 2.44B 467M
Hikma Pharmaceutical HIK:LN USD 253M 3M
Merck MRK:GR EUR 1.57B 19M
Orion ORNBV:FH EUR 77M 800K
Recordati REC:IM EUR 144.95M 131K
Roche Holding ROG:VX 6.48B 834M